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Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic
inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response against the
tumor and immunosuppression is known to increase the risk for certain tumors.
This article reviews current literature on the role of inflammation in cancer and the cancer risk in immune-mediated
inflammatory diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of
IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors.
Overall cancer incidence and mortality risk are similar to the general population in inflammatory bowel disease
(IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor
types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the
combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF
treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a
history of cancer are scarce.
This review provides clinicians with a solid background to help them in making decisions about treatment of
immune-mediated diseases in patients with a tumor history.
This article is related to another review article in Molecular Cancer: http://www.molecular-cancer.com/content/12/1/86.
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Tumor necrosis factorIntroduction
Immune-mediated inflammatory diseases (IMIDs) are a
group of chronic and highly disabling diseases involving
inappropriate or excessive immune responses caused or
accompanied by cytokine dysregulation and acute or
chronic inflammation [1]. This includes a wide variety of
illnesses, such as Crohn’s disease (CD), ulcerative colitis
(UC), psoriasis, rheumatoid arthritis (RA), and systemic
lupus erythematosus (SLE). IMIDs are fairly common,
affecting an estimated 5% to 7% of the population in
Western countries. Treatment of IMIDs focuses on the
rapid control of inflammation, prevention of tissue
damage, and where possible, long-term remission of the* Correspondence: filip.dekeyser@ugent.be
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reproduction in any medium, provided the ordisease. This is achieved using corticosteroids, immuno-
suppressants, and “biologicals”, especially those targeting
tumor necrosis factor (TNF).
Because immunosurveillance is thought to help sup-
press the development of cancer, there are concerns that
immunotherapies might increase cancer risk in patients
with IMIDs. Furthermore, inflammation is known to
have both pro- and anti-tumorigenic effects, and cancer-
related inflammation is now considered the seventh hall-
mark of cancer [2].
In this article, we discuss the current state of know-
ledge concerning the relationship between IMIDs and
cancer. This information should help clinicians decide
about the safety of giving immunosuppressive therapies
to IMID patients with a history of tumors.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Inflammation can occur in response to dietary or envir-
onmental factors, infection, and autoimmune diseases
including IMIDs. Inflammatory cells are present in most,
if not all, solid tumors [3]. Tumor-associated macro-
phages can comprise up to as much as half of the mass
of a solid tumor [4]. These cells promote tumor cell sur-
vival, proliferation, and dissemination, and a high level
of them is associated with a poor prognosis. Tumor-
associated inflammatory cells appear to be actively
recruited, possibly as part of an anti-tumor response, but
this inflammatory response may be usurped by the
tumor to promote tumorigenesis [3].Anti-tumorigenic effects of inflammation
Activation of inflammatory cells as part of an immune
response to eliminate mutant cells, a process called
immunosurveillance, was originally suggested by Ehrlich
and later formalized by Burnet and Thomas [5]. Aber-
rant proteins or peptide-MHC complexes on the sur-
faces of transformed or malignant cells are recognized
and targeted for elimination by the immune system. Evi-
dence that the immune system recognizes and eliminates
tumor cells was originally obtained in mice, but this is
also supported by several lines of clinical evidence: can-
cer incidence is increased in transplant patients treated
with immunosuppressants; cancer patients develop im-
mune responses to tumors; immune responses in tumors
correlate with improved prognosis in colorectal cancer;
survival positively correlates with the presence of tumor-
infiltrating lymphocytes, CD8+ T cells, and natural killer
cells in various cancers; higher natural cytotoxic activity
of peripheral blood lymphocytes correlates with a re-
duced cancer risk [6-8].
Murine studies found that tumors formed in the
absence of an intact immune system are more immuno-
genic in wild-type mice than those formed in the pres-
ence of an intact immune system [9-13]. In other words,
the immune response eliminated the more immunogenic
cells and selected less immunogenic cells, a process that
Dunn and colleagues refer to as “immunologic sculpting”
or “immunoediting” [7]. Immunoediting is composed of
three phases: “elimination”, “equilibrium”, and “escape”.
The initial phase of an immune response to a tumor,
elimination, is the same as immunosurveillance and
results in destruction of (part of ) the tumor cells [7].
Dunn and colleagues envision that the tumor thereafter
remains in equilibrium with the immune system,
wherein selection pressure continues but is unable to
eliminate the tumor. In this equilibrium phase, some
tumor cells are eliminated and others, including new
variants, survive. In the final escape phase, the selectedtumor cell variants have become resistant to elimination
by the immune system.
Efficient inhibition of tumor growth was recently
shown to involve not only defined cell death and clear-
ance mechanisms by CD8+ cytotoxic T lymphocytes and
natural killer cells, but also the induction of tumor cell
senescence by interferon-γ and TNF producing CD4+
T-helper 1 cells. In addition, T-helper 1 immunity can
also induce anti-angiogenic chemokines that protect
against cancer [14].
Pro-tumorigenic effects of inflammation
A wide range of studies indicate that inflammation also
contributes more directly to tumorigenesis [15]. Nearly
one in five cancers is linked to infections: e.g.
Helicobacter pylori and Hepatitis C virus infections
eventually lead to gastric and liver cancers, respectively
[16,17]. Also, many cancers are associated with persist-
ent inflammation due to environmental factors or auto-
immune reactions: e.g. lung cancer is associated with
asbestosis and smoking, colon cancer with inflammatory
bowel disease (IBD), and lymphoma with celiac disease
[8,17]. Furthermore, numerous experimental and epide-
miologic studies, along with randomized clinical trials
showed that long-term daily use of the nonsteroidal
anti-inflammatory drug aspirin reduced the incidence of
several cancers, especially those of the gastrointestinal
tract [18-21]. The mechanism of action of the
chemopreventive and anticancer effects of aspirin is not
fully understood, but it has been attributed to its
anti-inflammatory effects, specifically inhibition of
prostaglandin-endoperoxide synthase 2 (formerly named
cyclooxygenase 2), which is the rate-limiting step for the
conversion of arachidonic acid to prostaglandins. Be-
cause aspirin can cause stomach upset and dangerous
internal bleeding, its use as anticancer drug for the gen-
eral population is still under debate [22]. Together, these
findings suggest that when inflammation becomes per-
sistent or dysfunctional, it can promote tumor growth,
as inflammatory cells, normally recruited to control
damage, are diverted by the tumor for pro-tumorigenic
purposes [3,23].
How chronic inflammation increases cancer risk is be-
ginning to come into focus [3,15]. Chronic inflammation
can initiate tumors by directly causing DNA changes or
making cells more susceptible to mutagens. In addition,
inflammation can act as a tumor promoter. Inflamma-
tory mediators, including cytokines like TNF, interleukin
(IL)-1, and IL-6, growth factors, chemokines, and prote-
ases produced by tumor-associated lymphocytes and
macrophages can enhance tumor cell growth and metas-
tasis by promoting their survival, proliferation, migration
to and invasion of other tissues. Tumor-associated mac-
rophages release inflammatory mediators that stimulate
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produce cytokines, including transforming growth factor
(TGF) β and IL-10, that can directly suppress immune
responses [24]. Also, myeloid-derived suppressive cells,
which accumulate in infections, inflammatory and
autoimmune diseases, and cancer, can inhibit tumor
immunosurveillance and suppress natural killer cells [25].
At the molecular level, the transcription factor NF-κB
appears to be a key connecting element between inflam-
mation and cancer [26]. NF-κB is a central intracellular
transducer of inflammatory signals [27], integrating sig-
nals from a variety of environmental changes, including
infection, tissue damage and autoimmunity [26]. Several
proinflammatory cytokines such as TNF and IL-1 are
potent activators of NF-κB, which regulates the tran-
scription of a variety of inflammatory genes, including
TNF and IL-1 themselves, thus further amplifying the
proinflammatory signal [26-28]. Not surprisingly, NF-κB
is activated in many inflammatory diseases, and inhibi-
tors of NF-κB have beneficial effects in mouse models of
inflammation [29]. Additionally, mutant forms of NF-κB,
NF-κB inhibitor proteins such as IκBα and A20, or up-
stream signaling components that feed into NF-κB, are
found in many cancers [30]. NF-κB activation is thought
to act as a tumor promoter by enhancing tumor cell sur-
vival and proliferation and helps convert tumor-associated
macrophages to a tumor-promoting phenotype [26]. Des-
pite these pro-oncogenic roles, drugs specifically targeting
NF-κB have had limited success in treating cancer,
although ubiquitin-proteasome targeting drugs such as
bortezomib and carfilzomib, which act in part by
preventing NF-κB activation, have been successfully ap-
proved for clinical application while some other promising
candidates are currently under clinical trials [31].
NF-κB also regulates the expression of IL-6, a multi-
functional cytokine that plays important roles in im-
mune responses, cell survival and proliferation. Mouse
studies demonstrated that IL-6 is important for both
tumor development and growth in colitis associated can-
cer, with IL-6 promoting both proliferation and survival
of intestinal epithelial cells via the activation of the tran-
scription factor STAT3 [32,33]. Although in many
cancers STAT3 is not directly activated by oncogenic
mutations, it exerts critical oncogenic functions in both
cancer and immune cells within the microenvironment
[34]. More recently, mouse studies also demonstrated a
critical role for IL-23 and its downstream cytokines
IL-17 and IL-22 in the development of colitis-associated
cancer [35], increasing the number of cytokines that link
inflammation with the development of cancer.
IMIDs and Cancer Risk
IMIDs are characterized by severe inflammation [1].
Given the molecular and cellular links betweeninflammation and cancer, it is not surprising that many
IMIDs are associated with an increased risk of cancer
(Table 1), although confounding effects of treatment are
hard to eliminate.
Rheumatoid arthritis
Although its triggers are unknown, RA is considered the
archetypal IMID in which autoimmunity induces the
production of the pro-inflammatory cytokines TNF, IL-1,
and IL-6, triggering the production of degradative en-
zymes that destroy the joints and further stimulate the
T cell response [1].
Two Swedish population-based studies found that pa-
tients with RA are at an approximately two-fold in-
creased risk for lymphoma and leukemia, a 20% to 50%
increased risk for respiratory tract cancer, and a 70% in-
creased risk for non-melanoma skin cancers (NMSC),
but at decreased risk for breast and colorectal cancer
[30,32]. A meta-analysis including 21 publications con-
firmed the increased risk for lymphoma and lung cancer
and decreased risk for colorectal and breast cancer in
RA [33]. Increased lymphoma risk is limited, however, to
the subset of RA patients with longstanding and very se-
vere disease [34].
Inflammatory bowel diseases
Crohn’s disease and ulcerative colitis represent the two
principal forms of IBD [35]. Both are chronic inflamma-
tory diseases apparently caused by an inappropriate
immune response, probably to a gut antigen that is nor-
mally suppressed [1]. Both diseases are characterized by
severe gastrointestinal inflammation, although they also
have systemic manifestations affecting the skin, eyes,
joints, liver, hepatobiliary system [1,67].
Overall cancer incidence rates are increased in CD,
but similar to the general population in UC [68]. Meta-
analyses indicate that patients with CD are at increased
risk for colorectal and fistula cancer and for cancer of
the small bowel, upper gastrointestinal tract, lung, blad-
der and skin [42-44]. A Swedish registry study of more
than 27,000 CD patients hospitalized between 1964 and
2004 found elevated risks for liver, pancreatic, prostate,
testicular, and kidney cancers, nonthyroid endocrine tu-
mors, and leukemia [45].
Patients with UC have an increased risk of colorectal
carcinoma, liver-biliary cancer, and leukemia but a re-
duced risk of pulmonary cancer [42,66]. The risk of colo-
rectal cancer in UC is further elevated in patients with
dysplasia and ongoing mucosal inflammation [69-71].
Psoriasis
Psoriasis is a chronic inflammatory skin disease charac-
terized by circumscribed, erythemato-squamous plaques
with adherent scales [72]. Psoriasis appears to be driven
Table 1 Examples of IMIDs associated with increased risks
for cancer
IMID Associated malignancies
Aplastic anemia Myeloproliferative disorders [36]
Autoimmune hepatitis Non-melanoma skin cancer, hepatocellular
carcinoma [37,38]
Celiac disease Non-Hodgkin’s lymphoma, esophageal
cancer, Hodgkin’s lymphoma, small bowel
carcinoma, stomach cancer [39-41]
Crohn’s disease Colorectal and fistula cancer and for
cancer of the small bowel, upper
gastrointestinal tract, lung, urinary bladder
and skin [42-44]. Liver, pancreatic, prostate,
testicular, and kidney cancers, nonthyroid
endocrine tumors, and leukemia [45].
Dermatomyositis Ovarian, lung, gastric cancer [46]
Giant cell arteritis Myeloproliferative disorders [36]
Immune thrombocytopenic
purpura
Myeloproliferative disorders [36]
Polymyalgia rheumatica Myeloproliferative disorders [36]
Primary biliary cirrhosis Hepatocellular carcinoma [38]
Psoriasis Colon cancer [47] and possibly cancer of
the urinary bladder, kidney, oropharynx/
larynx, esophagus, stomach, liver/
gallbladder, vulva, female breast, and
pancreas and for leukemia, non-Hodgkin’s
lymphoma, and non-melanoma skin
cancer [48-57]
Reiter’s syndrome Myeloproliferative disorders [36]
RA Lymphoma and leukemia, non-melanoma
skin cancers [32,33,58]; lymphoma and
lung cancer [33]
Sarcoidosis Rectal, colon, kidney, skin (squamous cell),
nonthyroid endocrine cancer; non-
Hodgkin’s lymphoma; leukemia [59]
Sjögren syndrome lymphoproliferative disorders [46]
SLE Hematological malignancies, including
non-Hodgkin’s lymphoma, and cancers of
the vagina/vulva/cervix, nasopharynx, and
kidney [60-62]
Systemic sclerosis Lung, skin, esophageal, non-melanoma
skin, and liver cancer [40,46,63]
Type 1 diabetes mellitus Pancreatic cancer [64,65]
Ulcerative colitis Colorectal carcinoma, liver-biliary cancer,
and leukemia [42,66]
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by IFN-α, although several other inflammatory mediators,
including TNF, are also involved. Psoriasis may be associ-
ated with systemic manifestations, including an increased
risk for metabolic syndrome, cardiovascular disease and
systemic inflammation similar to that observed in RA.
Several studies from the pre-biologics era implicated
an increased risk for lymphoma, NMSC and cancers re-
lated to alcohol and smoking in psoriasis patients [48].
Cancer risk seems to be higher in patients with severe
psoriasis, which raises the question whether this iscaused by chronic inflammation or by the systemic treat-
ments more often used in severe psoriasis [49,73].
The Iowa Women’s Health Study, which included
more than 32,000 women, found a significant association
only between colon cancer and psoriasis when disease
incidence was adjusted for smoking, body mass index,
education, physical therapy, and use of hormone therapy
[47]. Other studies suggest an increased risk for cancer
of the bladder, kidney, oropharynx/larynx, esophagus,
stomach, liver/gallbladder, vulva, breast, and pancreas
and for leukemia, non-Hodgkin’s lymphoma, and NMSC
[48-55]; however, these studies did not control for envir-
onmental factors such as alcohol and smoking. Although
concern has been raised that psoriasis treatment with
PUVA (psoralen + ultraviolet light), methotrexate, or
cyclosporine can increase cancer risk [74,75]; the most
recent studies have shown that these treatments are not
associated with an increased risk [50,76,77].
Very recently, a systematic literature review with
meta-analysis was performed on the risk of cancer in
psoriasis [56], accompanied by evidence-based recom-
mendations [57]. Together, the authors concluded that
there is a slightly increased risk of some cancers in pa-
tients with psoriasis (upper aero-digestive tract, liver,
lung, pancreatic and urinary tract cancers), that the
highest increased risk is for skin carcinoma, that there is
no increased risk of melanoma and that regarding
lymphoma, misdiagnosis of primary skin lymphoma as
psoriasis might have overestimated the risk.
Systemic Lupus Erythematosus (SLE)
SLE is another chronic inflammatory disease triggered
by an autoimmune reaction and mediated by inflamma-
tory cytokines, especially TNF, IL-1 and type 1 inter-
ferons [78]. SLE can affect almost any tissue and is most
often characterized by fatigue coupled with musculoskel-
etal, skin, pulmonary, cardiac, gastrointestinal, renal,
neuropsychiatric, or reproductive manifestations [79].
SLE is associated with an increased risk of hematological
malignancies, including non-Hodgkin’s lymphoma, and
cancers of the vagina/vulva/cervix, nasopharynx, and
kidney [60-62], but a decreased risk of breast, ovarian,
and endometrial cancer [80].
IMID treatments and cancer risk
Risk of cancer associated with immune suppression:
transplantation as a model
Treatment of IMIDs focuses on inhibiting inflammation
by suppressing the activity and proliferation of immune
cells and the cytokine production involved in innate and
adaptive immune responses [81]. Before the advent of
biologics, this could only be accomplished with im-
munosuppressant drugs. However, experience in trans-
plant patients indicates that these drugs increase the risk
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Barr virus-associated post-transplant lymphoproliferative
disorder [82]. This effect of immunosuppressants pro-
vides support for the immunosurveillance hypothesis
[5,83,84].
Immune modulators
Thiopurines
The thiopurines azathioprine, 6-thioguanine, and 6-mer-
captopurine are immunosuppressive drugs commonly used
for the treatment of autoimmune diseases, for the pre-
vention of transplant rejection and the treatment of
lymphoproliferative disorders [85]. Thiopurines act in sev-
eral ways to interfere with lymphocyte proliferation. Accu-
mulating evidence shows that they increase the cancer risk
in IMID patients. IBD patients treated with thiopurines
have an increased risk for NMSC and lymphoma [86,87].
A 2005 meta-analysis of cohort studies found that
treatment of IBD with azathioprine or 6-MP increased
the risk of lymphoma (RR = 4.2), although it was not
clear whether the increased risk was due to the medica-
tions, the severity of the underlying disease, or a com-
bination of both [88]. This conclusion was supported by
a French observational study of 19,486 IBD patients
followed up for a median of 35 months, which found an
increased risk of lymphoproliferative disorders in pa-
tients receiving thiopurines compared to those who had
never received them (HR = 5.28) [86]. In addition, two
retrospective analyses reported an increase in NMSCs
associated with IBD treatment (adjusted OR = 4.3 and
OR = 5.0, respectively) [87,89].
Cyclosporine
Cyclosporine is a calcineurin inhibitor that inhibits in-
flammation by blocking IL-2 production by activated
CD4+ T cells [75]. In transplant patients, cyclosporine
increases the risk of lymphoma, internal malignancies,
and skin cancers [75]. A 2003 report found that in pa-
tients with psoriasis, cyclosporine increases the risk of
skin cancer 6-fold [90]. The risk increased with treat-
ment duration over 2 years and prior phototherapy. A
more recent systematic review found that cyclosporine
significantly increases the risk for NMSC in RA [91].
Methotrexate
Methotrexate is a folic acid analog that suppresses
cell proliferation by inhibiting DNA synthesis [75].
Melanoma and Epstein-Barr virus-associated lymphomas
in psoriasis patients taking methotrexate have been
reported [92]. However, a Canadian observational study
including 23,810 patients with RA did not find an in-
creased risk for hematologic malignancies in patients
treated with methotrexate [92]. This was also found in a
2009 meta-analysis by Salliot and van der Heijde, whichreported no increase in the risk of lymphoma or malig-
nancies in RA patients treated with methotrexate [93].
However, a 2010 systematic review by Krathen et al. sug-
gested that methotrexate in RA may increase the risk of
malignant melanoma, and double the risk for NMSC
when combined with anti-TNFs; in patients with psoria-
sis methotrexate increased the risk of NMSC [94].
Cyclophosphamide
Cyclophosphamide suppresses immune function by
inhibiting lymphocyte proliferation [95]. A Canadian ob-
servational study including 23,810 RA patients reported
an increased risk of hematologic malignancies (un-
adjusted OR = 2.21) in patients treated with cyclophos-
phamide [92]. Cyclophosphamide is known to increase
bladder cancer risk, and patients who have received this
drug should be monitored regularly for microscopic
hematuria [96].
Biologics Targeting TNF
TNF, as its name implies, was discovered as a serum fac-
tor from lipopolysaccharide-treated mice that causes
tumor necrosis [97], and was originally intensively stud-
ied because of its potential use as anti-tumor agent [98].
However, initial enthusiasm about its clinical use as anti-
tumor agent was curbed due to significant toxicities and
lack of efficacy of systemic treatment. Clinical use of
TNF for cancer treatment is therefore limited to the
setting of hyperthermic isolated limb perfusion for the
regional treatment of locally advanced soft tissue sarco-
mas, metastatic melanomas and other irresectable tu-
mors to avoid limb amputation [99]. Moreover, a
paradoxical tumor-promoting role of TNF became ap-
parent, which may reflect the role of TNF as a key pro-
inflammatory mediator and the tumor-promoting role of
inflammation [100]. TNF is a key mediator of inflamma-
tion, which is barely detectable in circulation under nor-
mal conditions, but is produced by macrophages,
activated T cells, natural killer cells, mast cells, and stro-
mal cells during innate or adaptive immune responses
[101,102].
TNF acts on multiple cell types by binding to specific
cell surface receptors that activate multiple signaling
pathways that culminate in the activation of MAP kin-
ase, NF-κB and other transcription factors. At high
doses, TNF causes the death of tumor blood vessels, al-
though at lower doses, it can act as a tumor promoter
and enhancer of metastasis [16]. Furthermore, certain
polymorphisms in the TNF gene are associated with he-
patocellular cancer [103-106], non-Hodgkin’s lymphoma
[107], breast cancer [108], and gastric cancer [109].
TNF is an important mediator of the dysregulated im-
mune and inflammatory function in IMIDs. Drugs that
target TNF are the most widely used biologics for
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clinical treatment of IMIDs (Table 2) [110]. Although
anti-TNF therapy is used in different IMIDs, not all anti-
TNF agents have the same efficacy in all IMIDs [111].
Studies on the effect of TNF-blockers on the incidence
of malignancy began to appear in the late 1990s.
Bickston et al. reported the occurrence of lymphoma
after infliximab treatment in patients with CD in 1999
[112]. Other individual reports of lymphoproliferative
diseases in patients treated with infliximab or etanercept
followed soon thereafter [113-115]. A large prospective
observational study including 18,572 patients from the
US National Data Bank for Rheumatic Diseases found a
2.9-fold increase in the incidence of lymphoma in pa-
tients treated with etanercept or infliximab [116]. Up-
dates three years later from this same database found
the contrary – that infliximab and etanercept, after a
median exposure of three years, were not associated with
a risk of lymphoma in patients with RA [117,118]. Two
additional observational studies reported that anti-TNF-
biologics do not increase the risk of solid cancer, lymph-
oma or leukemia [30,32].
Thus, while some of the studies suggested a link be-
tween the use of anti-TNF biologics and cancer, others
did not. Interpretation and reconciliation of these differ-
ent findings is difficult because randomized clinical trials
are usually too small or brief to obtain sufficient data to
accurately determine the effects of a treatment on cancer
and because most observational studies usually lack
adequate control groups. Meta-analyses have therefore
been performed on pooled data from multiple rando-Table 2 Biologics used in the treatment of IMIDs
Biologic Type of molecule
Infliximab (Remicade®) Chimeric monoclonal antibody a
Adalimumab (Humira®) Human monoclonal antibody ag
Golimumab (Simponi®) Human monoclonal antibody ag
Certolizumab pegol (Cimzia®) Pegylated humanized Fab’ mono
antibody fragment against TNF
Etanercept (Enbrel®) Fusion protein of two TNF recep
domains and the Fc portion of h
Tocilizumab (Actemra® or RoActemra®) Humanized monoclonal antibod
the interleukin-6 receptor
Rituximab (Rituxan® or MabThera®) Chimeric anti-CD20 monoclonal
Abatacept (Orencia®) Fusion of extracellular domain o
CTLA-4 and the Fc domain of Ig
Alefacept (Amevive®) Fusion of CD2-binding region of
CH2 and CH3 domains of IgG1
Anakinra (Kineret®) Recombinant, non-glycosylated
receptor antagonistmized clinical studies or prospective observational stud-
ies to better assess the risks of cancer associated with
the treatment of IMIDs by biologics (Table 3).
An initial meta-analysis published in 2006 by Bongartz
et al. [119] reported a 3.3-fold dose-dependent increase in
malignancies associated with infliximab in RA patients. A
2011 meta-analysis by Mariette et al. [124] analyzing data
from 21 prospective observational studies on anti-TNF bi-
ologics in RA found that although anti-TNF biologics are
not associated with an increase in malignancies, especially
lymphoma, they are associated with an increase in the risk
of skin cancer, including melanoma.
Meta-analyses of randomized clinical trials, however,
found that the treatment of RA with anti-TNF biologics
[121,126,129] or biologics overall [128] does not signifi-
cantly increase the risk for any type of cancer in RA pa-
tients An important limitation of the RCT data in these
studies, however, is the shortness of the follow-up period
of the included studies in comparison with the latency
period for emergence of cancer.
An integrated analysis of three patient databases found
that the risk of malignancy in RA patients treated with
anti-TNF biologics does not increase with time [130].
The risk for cancer for individual anti-TNF biologics
other than infliximab has been assessed in a few studies.
An observational in 2004 found an increased risk of
lymphoma associated with etanercept therapy in RA
[116], this was not supported by their 2007 updates from
the same observational database, although they did find
an increased risk of skin cancer [117,118]. A meta-
analysis of randomized clinical trials from 2009 foundIMIDs for which it is licensed
gainst TNF RA, psoriatic arthritis, ankylosing spondylitis,
ulcerative colitis, Crohn’s disease, plaque psoriasis
ainst TNF RA, psoriatic arthritis, ankylosing spondylitis,
Crohn’s disease, ulcerative colitis, plaque psoriasis,
polyarticular juvenile idiopathic arthritis
ainst TNF RA, psoriatic arthritis, ankylosing spondylitis
clonal RA, Crohn’s disease
tor 2 extracellular
uman IgG
RA, polyarticular juvenile idiopathic arthritis,
psoriatic arthritis, ankylosing spondylitis,
plaque psoriasis
y against Juvenile idiopathic arthritis, RA
antibody RA, granulomatosis with polyangiitis (Wegener)
f human
G
RA
LFA-3 and the Psoriasis
human IL-1 RA
Table 3 Meta-analyses on cancer risks associated with the use of biologics to treat IMIDs
Study Disease Study types included Medication Findings
Bongartz et al. 2006 [119] RA Prosp Obs Infliximab Adalimumab Increased risk of malignancies
Peyrin-Biroulet et al. 2008 [120] Crohn’s disease RCTs Infliximab, adalimumab,
certolizumab, CDP571
No increase in malignancy
Leombruno et al. 2009 [121] RA RCTs Etanercept, infliximab,
adalimumab
No increased risk of melanoma,
lymphoma, non-lymphoma skin
cancer, or cutaneous cancer +
melanoma
Bongartz et al. 2009 [122] RA RCTs Etanercept for ≥ 12 weeks Non-significant increase in cancer
Siegel et al. 2009 [123] Adult Crohn’s disease RCTs Infliximab, adalimumab,
certolizumab
Increase risk of non-Hodgkin’s
lymphoma
Mariette et al. 2011 [124] RA Prosp Obs Anti-TNF No increase in malignancy (including
lymphoma). Increase in skin cancer
(including melanoma)
Dommasch et al. 2011 [125] Plaque psoriasis,
psoriatic arthritis
RCTs Etanercept, Infliximab,
adalimumab, certolizumab,
golimumab
No increase in cancers for
short-term use
Askling et al. 2011 [126] Any RCTs etanercept, infliximab,
adalimumab
No increase in cancer with
short-term use
Campbell et al. [127] RA RCTs Tocilizumab No increase in risk of malignancy
Lopez-Olivo et al. [128] RA RCTs Adalimumab, Certolizumab,
Etanercept, Golimumab,
Infliximab, Abatacept,
Anakinra, Rituximab,
Tocilizumab
No increased risk of malignancy in
comparison with DMARDs or
placebo
Moulis et al. 2012 [129] RA RCTs Anti-TNF No excess cancer risk in either per
protocol or intention to treat
analysis, non-significant trend for
increased non-melanoma skin cancer
Abbreviations: DMARDs Disease-modifying anti-rheumatic drugs, IMID immune-mediated inflammatory disease, RCT randomized clinical trial, Prosp Obs prospective
observational trial.
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tients with RA was associated with a non-significant in-
crease in the incidence of cancer [122]. Also, a 2010
report found that the use of golimumab at the FDA-
approved dose to treat RA was not associated with a dif-
ference in the rate of cancer rate [131].
A prospective observational study in France by Mariette
et al. [132] found that patients receiving adalimumab or
infliximab have a higher risk for lymphoma than those
treated with etanercept and that exposure to adalimumab
or infliximab versus etanercept was an independent risk
factor for lymphoma. The 2011 meta-analysis by Askling
et al. [126] did not find differences between the anti-TNF
antibodies adalimumab, etanercept, and infliximab, al-
though they suggest that this may have been due to differ-
ences in statistical precision or in baseline cancer risk
between the various studies.
Few studies have examined the risk of cancer associ-
ated with the use of anti-TNF biologics in IMIDs other
than RA. A 2008 meta-analysis of randomized clinical
trials by Peyrin-Biroulet et al. reported that the treat-
ment of CD by anti-TNF biologics does not increase therisk for cancer [120]. However, a more recent meta-
analysis of randomized clinical trials by Siegel et al.
found that treatment of CD with anti-TNF biologics in
combination with immunomodulators is associated with
an increased risk of non-Hodgkin’s lymphoma [123].
Analysis of data from the FDA Adverse Event Reporting
System (AERS) showed that treatment with a combin-
ation of thiopurines and TNF inhibitors, but not with
TNF inhibitors alone is associated with increased risk of
non-Hodgkin lymphoma in IBD patients [133]. Also, a
meta-analysis of randomized clinical trials in plaque
psoriasis and psoriatic arthritis found that short-term
anti-TNF biologic use is not associated with a significant
increased risk of cancer [125].
Biologics targeting molecules other than TNF
Alefacept
Alefacept is a human fusion protein of the CD2-binding
region of LFA-3 and the CH2 and CH3 domains of
IgG1. It inhibits T cell activation and induces apoptosis
of memory T cells and has been approved for the
treatment of psoriasis [134]. Very little information is
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an integrated analysis of data from 13 clinical trials in-
cluding 1869 patients found that this agent does not
cause a dose-dependent increase in the incidence of ma-
lignancy [135].
Rituximab
Rituximab is a chimeric monoclonal antibody against the
protein CD20 that induces B cell killing and has been ap-
proved for the treatment of RA refractory to anti-TNF
treatment [136]. Few data are available on whether rituxi-
mab use in RA patients affects the risk of cancer, although
a recent analysis of 186 patients followed for an average of
22 months found no increase in the overall cancer rate
compared to patients treated with disease-modifying anti-
rheumatic drugs (DMARDs) [137].
C Tarella et al. [138] described the long-term outcome
of a large series of patients with lymphoma who received
an intensive chemotherapy schedule, with or without
addition of four to six doses of rituximab. In this study,
rituximab addition was associated with an increased risk
of solid tumor occurrence both in univariate and multi-
variate analysis. Conversely, rituximab had a significant
protective role on the risk of death. This finding in
lymphoma patients is noteworthy and should be further
explored. Caution is therefore also warranted in other
disease backgrounds. The different patient background
and the combination of rituximab with particular anti-
cancer drugs in the lymphoma population, however,
precludes simple extrapolation of the data from the
lymphoma population to the IMID field.
Abatacept
Abatacept is a fusion protein of IgG and the extracellular
domain of CTLA-4 that inhibits T cell activation ap-
proved for treatment of moderate to severe RA [139].
An integrated analysis of five registries comprising 4134
RA patients found similar overall rates of cancer in pa-
tients treated with abatacept as in the general RA popu-
lation [140]. A long-term extension of an RCT with a
five-year follow-up period, showed no increased malig-
nancy rates under abatacept treatment [141].
Ustekinumab
Ustekinumab is a blocking antibody to the IL-12/IL-23
receptor approved for the treatment of plaque psoriasis
[142]. Cumulative safety data from four phase II and III
studies including 3117 patients shows no increase in ma-
lignancy rate during the first four years of ustekinumab
treatment [143].
Anakinra
Anakinra is a competitive inhibitor of IL-1 binding to
the IL-1 receptor approved for the treatment of RA[144]. Prospective observational data from the German
database RABBIT demonstrated no increase in the overall
cancer rate in RA patients treated with anakinra [145].
Tocilizumab
Tocilizumab is a humanized mouse monoclonal anti-
body to the IL-6 receptor that blocks ligand binding
[146][133]. A 2010 meta-analysis and systematic review
of randomized clinical trials found that tocilizumab does
not significantly increase the rate of malignancies [127].
Biologics in patients with cancer history
A 2010 study of data from the British Society for
Rheumatology Biologics Register reported that in pa-
tients with RA, prior malignancy and an average of three
years of follow up, the malignancy incidence rate did not
increase in patients receiving anti-TNF therapy [147].
The authors concluded that the way in which the pa-
tients were selected for anti-TNF therapy is not leading
to an increased risk of incident malignancy but cau-
tioned against concluding that it is safe to use anti-TNF
biologics for RA patients with prior malignancy.
Up to now there is no clear evidence to guide the deci-
sion whether or not to use immunosuppressants or
biologics in patients with previous history of cancer.
Treatment decisions in these patients must taken on a
case-by-case basis after discussion with a multidisciplin-
ary team, taking into account the need for such treat-
ment, the risk of cancer recurrence and the sensitivity of
a specific cancer to immunosuppression, finally weighing
benefits versus risks for the patient.
Conclusion
The evidence provided in this manuscript leads to the
conclusion that some IMIDs are associated with an in-
creased cancer risk and that the cancer risk associated
with immunotherapy should be discussed in relation
with each individual conventional or biological drug.
Overall cancer incidence and mortality risk are similar
to the general population in IBD, and slightly increased
for RA and psoriasis.
RA entails a twofold increase in lymphoma risk and an
increased risk for lung cancer. Anti-TNF treatment of
RA does not increase overall cancer risk, but increases
the risk of NMSC, especially when combined with
methotrexate.
In IBD, overall cancer risk is elevated in CD but not in
UC. IBD patients run an increased risk for gastrointes-
tinal malignancies driven by chronic intestinal inflamma-
tion. Thiopurines increase the risk for NMSC, while
limited data are available on the effect of anti-TNF treat-
ment on cancer risk in IBD.
Psoriasis increases the risk for some cancers, such as
NMSC and alcohol or smoking-related tumors. Higher
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confounded by the effect of systemic treatment. PUVA,
cyclosporine and anti-TNFs increase NMSC risk in psor-
iasis patients.
Data on the safety of using biologic or immunosup-
pressant therapy in IMID patients with a history of
cancer are scarce.
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